Government ❯ Regulatory Agencies ❯ FDA ❯ Drug Approval Process
Novo Nordisk files for FDA approval of its oral anti-obesity medication, following Eli Lilly's phase III success with orforglipron, the first oral GLP-1 to achieve this milestone.
